Which generation of targeted drug is Lorlatinib?

Lorlatinib (Lorlatinib) is a third-generation targeted drug in the treatment of lung cancer. Lorlatinib is a third-generation targeted drug. Its development targets are not limited to EGFR mutations, but also ALK (tyrosine kinase) mutations and ROS1 ROS1 fusion genes. The development of these third-generation drugs aims to more comprehensively address the problem of drug resistance because they can interfere with multiple signaling pathways within tumor cells, thereby providing a more powerful inhibitory effect.

One of the characteristics of lorlatinib is its high selectivity for multiple targets, which allows it to achieve significant clinical efficacy in patients with ALK-positive non-small cell lung cancer (NSCLC). Additionally, lorlatinib has shown efficacy against some resistance mutations, further demonstrating its importance as a third-generation targeted agent.

In summary, lorlatinib represents the latest advancement in the field of targeted therapy, providing a treatment option that promises to improve survival and quality of life for patients with EGFR, ALK and ROS1 NSCLC. The development of third-generation targeted drugs marks a continuing evolution in lung cancer treatment, providing more opportunities to effectively control tumor growth and spread.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original drugs and cheaper generic drugs abroad. The cheaper ones are the original drugs from Turkey, which cost more than 1,000 yuan, and the original drugs from Hong Kong, China, which cost about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.